CCP
SRPT icon

Corient Capital Partners’s Sarepta Therapeutics SRPT Stock Holding History

Corient Capital Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,892
Closed -$261K – 765
2021
Q4 		$261K Buy
2,892
+333
+13% +$28.5K 0.02% 569
2021
Q3 		$237K Buy
+2,559
New +$197K 0.02% 581
2021
Q1 		– Sell
-1,213
Closed -$206K – 624
2020
Q4 		$206K Buy
+1,213
New +$180K 0.02% 473

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Corient Capital Partners's SRPT Position: Q1 2022 in Review

Corient Capital Partners sold out of Sarepta Therapeutics (SRPT) in Q1 2022, closing a stake of 2,892 shares — an estimated $261K sold.

Corient Capital Partners first reported a position in SRPT in Q4 2020 and held it in 3 quarters. The position peaked at $261K in Q4 2021. 328 funds tracked by Wall St. Rank hold SRPT as of Q1 2022.

  • Corient Capital Partners reported no remaining Sarepta Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Corient Capital Partners sold 2,892 Sarepta Therapeutics shares in Q1 2022, an estimated $261K.
  • Corient Capital Partners first reported a position in Sarepta Therapeutics in Q4 2020 and held it in 3 quarters.
  • Corient Capital Partners's Sarepta Therapeutics position peaked at $261K in Q4 2021.
  • 328 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2022.

Based on Corient Capital Partners's 13F filing for Q1 2022, filed 16 May 2022.